GlaxoSmithKline Stock News

Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedu

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedu

GSK (GSK) closed at $39.53 in the latest trading session, marking a -0.38% move from the prior day.

GSK PLC (LSE:GSK, NYSE:GSK) said it completed the sale of 300 million shares in Haleon, the consumer health giant, netting £978 million, or $1.23 billion, in the process. The sum is around $200 milli

British drugmaker GSK said on Wednesday it had raised 978 million pounds ($1.24 billion) from a discounted stake sale in Haleon , cutting its shareholding to 4.2% in the world's largest standalone con

UBS has revised its stance on two major UK-listed pharma companies - GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) - with an upgrade for the former and a downgrade for the latter. GSK i

GSK will sell a 3.2% stake, or about 300 million shares, in its spun-off consumer healthcare business Haleon , the British drugmaker said on Tuesday.

UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.

Shore Capital's recent research note on GSK PLC (LSE:GSK, NYSE:GSK) paints an optimistic picture for the pharmaceutical giant, underlining reasons for maintaining a 'Buy' recommendation with a raised

GSK has received a healthy price target upgrade from analysts at Deutsche Bank, which has the UK pharma as a top pick in a sector with a mixed outlook in 2024. “Top-down, our sector view remains neu

GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

International Wide-Moat Stocks On Sale - The January 2024 Heat Map